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In 1956, the diploid number of chromosomes in humans
was established as 46, opening the door for cytogeneticists
to identify numerical and structural chromosome abnor-
malities that lead to human disease. Nearly 6 decades of
critical discoveries describing the genetic underpinnings of
leukemia have followed this watershed moment and
provided drugable targets, including the Philadelphia
chromosome, PML-RARA, and FLT3. The management of
myelodysplastic syndrome (MDS) and acute myelogenous
leukemia (AML) relies on cytogenetic analysis, because
karyotype is a robust and independent predictor of
outcome. For patients with MDS and AML, morphology
alone is not sufﬁcient, and cytogenetic analysis is an integral
part of the diagnostic workup and disease monitoring.
Despite modern karyotyping techniques, however, roughly
half of patients with MDS and AML have a normal karyotype
at diagnosis, leading to imprecise rendering of their disease.
Somatic mutations identiﬁed via next-generation
sequencing have emerged, taking us into a new phase of
discovery and treatment for MDS and AML.SPLICING FACTOR MUTATIONS AND CLONAL EVOLUTION
OF MDS
The Oligoclonal Nature of MDS
Several groups have shown that cancer is rarely
a monoclonal population of cells, but is instead a mosaic of
clonal subpopulations with different mutational proﬁles [1-
7]. Next-generation sequencing technology has been
instrumental in deﬁning tumor clonality, providing a digital
representation of mutant allele burdens in tissues that
correlate with tumor cell content. Although several next-
generation platforms exist, investigators at Washington
University have focused on whole genome sequencing,
because it is a single platform that can detect all types of
genetic mutations, including structural variants, copy
number alterations, insertions/deletions, and single nucle-
otide variants (point mutations). Using this technology, we
now know that MDS samples, even those with normal
myeloblast counts or normal cytogenetics at presentation,
are highly clonal (composing up to 93% of cells in the bone
marrow) and contain hundreds of somatic mutations [2]. InFinancial disclosure: See Acknowledgments on page S37.
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relapse, we found that these diseases are typically oligo-
clonal, and in all cases an initial (“founding”) clone con-
taining hundreds of mutations is established that often
gives rise to one or more new (“daughter”) clones [1,2].
Most of these mutations are pathogenically irrelevant and
accumulated in normal hematopoietic stem/progenitor cells
before transformation [3], but their large numbers allow us
to identify with conﬁdence clonal populations of cells
(deﬁned as cells harboring clusters of mutations with
similar mutant allele burdens). Clonal evolution then occurs
(due either to selective pressure induced by chemotherapy,
in the case of relapsed de novo AML, or to the natural history
of the disease, in the case of sAML from MDS), characterized
by a single cell in the founding clone acquiring dozens to
hundreds of new mutations, some of which provide sufﬁ-
cient selective advantage allowing for outgrowth of new
daughter clones (Figure 1A). It is possible that disease
progression in patients with MDS is driven not only by the
presence of recurrent mutations, which have prognostic
value, but also by the clone (ie, founding versus daughter) in
which they arise. The elucidation of the number of clones
and their parenteoffspring relationship (the “clonal archi-
tecture” of a tumor) may have major clinical signiﬁcance,
since therapies that target and eliminate the founding clone
are predicted to be more effective than therapies that target
only the daughter clones.Splicing Gene Mutations
The discovery of novel mutations in MDS genomes has
accelerated recently with the use of next-generation
sequencing technology. Using exome sequencing, the
Ogawa laboratory reported mutations in 8 genes involved in
pre-mRNA splicing (ie, spliceosome genes) in patients with
MDS, including SF3B1 (29.4% of patients), SRSF2 (10.1%),
U2AF1 (8.8%), ZRSR2 (5.7%), U2AF2 (0.9%), SF1 (1.3%), SF3A1,
(1.3%), and PRPF40B (1.3%) [8]. These mutations tend to be
mutually exclusive of one another, indicating that they may
share a common mechanism of disease pathogenesis, or that
combinations of thesemutationsmay be lethal for a cell. Two
independent groups also have described mutations in SF3B1
in patients withg MDS and refractory anemia with ringed
sideroblasts (RARS) and RARS with thrombocytosis (RARS-T)
(65%-83% of patients with ringed sideroblasts) [9,10]. Using
whole genome sequencing, investigators at Washington
University identiﬁed U2AF1 mutations in 3 of 15 patients
with sAML that had progressed from de novo MDS. UsingTransplantation.
Figure 1. MDS clonality. (A) Clonal architecture of a sample containing 4 tumor clones present in the MDS sample. The percentage of cells harboring mutations,
indicated by the level of clonal hematopoiesis on the y-axis, was calculated by doubling the average mutant allele burden for dozens to hundreds of mutations for
each clone and inferring the parenteoffspring relationship. Green cells are normal hematopoietic stem cells. Yellow dots in a cell represent dozens to hundreds of
mutations in the founding clone. Orange, purple, and red dots represent mutations in daughter clones. At the time of AML transformation to sAML, the level of
clonality changes for all clones, with the emergence of a new clone not present in the paired MDS sample (black dot). Recurrently mutated genes present in clones are
indicated. During transformation, a clone carrying a NPM1mutation collapses (orange color), and another clone emerges (black color) that composes 50% of the sAML
sample. (B) Clonal architecture of a sample containing a U2AF1 mutation present in the founding clone (indicated by the yellow dot). (Modiﬁed with permission from
Walter MJ, Shen D, Ding L et al. Clonal architecture of secondary acute myeloid leukemia. N Engl J Med. 2012;366:1090-1098.)
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in 13 of 150 de novoMDS samples (8.7%), making U2AF1 one
of the most commonly mutated genes in MDS [11].
Furthermore, deep sequencing of DNA from unfractionated
bone marrow cells from our patients with de novo MDS
detected U2AF1 mutations in the founding clone in MDS,
indicating the mutations occurred early in the course of
disease, and RNA-seq demonstrated that the mutant allele is
expressed in all cases, suggesting that these mutations may
be important for initiation of MDS and progression to AML
(Figure 1) [2,11]. However, multivariate analysis (including
spliceosome mutations, other commonly mutated genes in
MDS, and standard prognostic variables) has not consistently
identiﬁed speciﬁc spliceosome mutations associated with
survival or transformation to AML, indicating the need to
study larger numbers of patients of MDS. Nonetheless, the
high recurrence rate and phenotypic association of spliceo-
somemutations inMDS (ie, SF3B1mutations in patients with
ringed sideroblastic diseases, and SRSF2mutations in CMML)
suggest that spliceosome genes are important for disease
pathogenesis.Targeting the Spliceosome
U2AF1 (U2AF35) encodes for a protein that is an auxiliary
factor for the U2 pre-mRNA splicing complex and is respon-
sible for recognizing the 30 AG dinucleotide at the splice
acceptor site in a pre-mRNA intron. Expression of mutant
U2AF1 inprimaryMDSsamples andmouse bonemarrowcells
was shown to alter mRNA splicing, providing evidence that
splicing changes are induced by mutations and suggesting
that they may contribute to disease pathogenesis [11]. It is
possible that spliceosomemutationsmay alter the abundance
of factors that provide a selective advantage to clonally
dominant cells (eg, tumor suppressors, transcription factors),
and that the splicing of modulator drugs could perturb these
dependencies and provide effective therapy in MDS. This
hypothesis canbe testedbydeterminingwhethermutant cells
are selectively sensitive to splicing modulator drugs that are
currently in preclinical development. If the hypothesis is
correct, then the results will support the paradigm that tar-
geting gene mutations present in the founding clone in MDS
could be a clinically relevant approach to pursue therapeuti-
cally. Our ability to track founding and daughter clones in
serial MDS samples also may help us understand why some
patients achieve a response to commonlyuseddrugs,whereas
others do not. It is possible that dynamic changes (or a lack of
changes over time) in clonal architecture will correlate withclinical response and help explain the clinical variability that
we observe.
CLINICAL IMPLICATIONS OF MUTATIONS IN MDS AND
AML: WHO ARE CONSIDERED CANDIDATES FOR
TRANSPLANTATION?
Molecular Genetics Deﬁning Prognosis in AML
Analyses conducted over a decade ago by the Medical
Research Council (MRC, 1998) and the Cancer and Leukemia
Group B (CALGB, 2002) set the standard for cytogenetic risk in
AML by separating patients into favorable-, intermediate-,
andpoor-risk groups based on karyotypeﬁndings. However it
was soon evident that further stratiﬁcationwas needed based
on the heterogeneous outcome of the intermediate-risk
group, comprised largely of patients with cytogenetically
normal AML (CN-AML, 48% of all patients). The incorporation
of three well-established molecular markers (FLT3-ITD,
NPM1, and CEBPA) into contemporary risk stratiﬁcation
systems has been a signiﬁcant step forward in better deﬁning
disease risk in patents with CN-AML [12]. Recently identiﬁed
mutations are also redeﬁning the risk in patients with
abnormal karyotypes similar to that of CN-AML. Mutations in
the KIT gene are found in approximately 20%-30% of patients
with core binding factor AML (CBF-AML) and are associated
with poor prognosis after chemotherapy with cumulative
incidence of relapse in both inv(16) (56% versus 29%) and
t(8;21) (70% versus 36%) [13]. This effect may vary among
classes of KITmutations [14].
lDH1 and IDH2 mutations [15], as well as DNAMT3A [16]
mutations, have been repeatedly identiﬁed as poor prog-
nostic markers, but where they fall within the greater
prognostic framework is unknown. As the cost of sequencing
technology decreases and throughput increases, new muta-
tions are regularly added to the litany of molecular markers
heightening the challenge of applying this information in
a meaningful way to everyday patient care. Methods that
integrate a large number of known biomarkers into predic-
tive models must be developed in parallel to identiﬁcation of
new mutations to best apply this escalating information -
better deﬁning a given patient’s disease risk, rather than
relying on individual or small sets of markers [17]. These
multigene mutation status predictor models have been
shown to improve upon existing cytogenetic risk models
[17,18]. Moreover, integrative prognostic models have proven
to be clinically successful in other settings such as the widely
adopted 21-gene recurrence score in breast cancer, and the
12-gene recurrence score for colon cancer currently under-
going validation. Given the large number of patients required
Table 1
Transplantation versus Chemotherapy: 2007 American Society for Blood and Marrow Transplantation (ASBMT) Position Statement and Current Indications
2007 ASBMT Position Statement* Current Indications
There is a survival advantage for allogeneic HCT versus chemotherapy
for patients aged <55 years with high-risk cytogenetics.
Patients with high-risk cytogenetic or molecular ﬁndings do poorly with
chemotherapy alone. Allogeneic HCT has improved outcomes in even the
highest-risk groups, such as those with monosomal karyotype, and conﬁrms
the position.
There is insufﬁcient evidence to routinely recommend allogeneic
HCT for patients with intermediate-risk cytogenetics, although
this is a reasonable strategy.
Mutations not detected by traditional cytogenetics allow for better
prognostication within the intermediate-risk cytogenetic group, identifying
those who beneﬁt from HCT (FLT/ITD) and those who do not (NPM1 and
CEBPA).
There is no survival advantage for allogeneic HCT in patients aged
<55 years with low-risk cytogenetics.
Given the poor prognosis of high leukocytosis in AML with t(8;21), it is
reasonable to consider allogeneic HCT. In core binding factor AML, KIT
mutations are associated with poorer outcomes and may be a potential
indication for HCT in the near future.
There are insufﬁcient data to make a recommendation for the use
of myeloablative regimens in patients aged >55 years.
Because reducing the intensity of conditioning may lead to higher rates of
relapse, it may be reasonable to pursue an allogeneic HCT with myeloablative
conditioning in a select population of more ﬁt patients as identiﬁed by
validated metrics, such as the HCT Comorbidity Index.
There are insufﬁcient data to make a recommendation for RIC
allogeneic HCT versus chemotherapy.
RIC regimens have demonstrated long-term remissions and decreased
transplantation-related mortality, resulting in similar overall survival as with
ablative regimens, extending the therapeutic beneﬁts of allogeneic HCT to
patients of advanced age or with medical comorbidities.
For patients in second complete remission, allogeneic HCT is
recommended if there is an available donor; otherwise,
autologous HCT is recommended.
With alternative donor sources, nearly every patient has a donor. These
transplantation techniques are rapidly improving and are currently being
investigated in a prospective study to assess beneﬁts and risks.
RIC indicates reduced-intensity conditioning.
Modiﬁed with permission from Gerds AT, Appelbaum FR, To transplant or not to transplant for adult acute myeloid leukemia: an ever-evolving decision. Clin Adv
Hematol Oncol. 2012;10:655-662.
* Oliansky DM, Appelbaum FR, Cassileth PA, et al. The role of cxytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acyte
myelogeous leukemia in adults: an evidence-based review. Biol Blood Marrow Transplant. 2008;14:137-180.
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tion methods and signiﬁcant collaborations will need to be
created prior to implementation of these metrics.
Traditional Cytogenetic Analysis: Neither Gone nor
Forgotten
Even with the advent of molecular prognostic markers
abnormalities detected by traditional cytogenetic studies
continue to be essential for the management of AML and
MDS as all but the most commonmolecular testing is neither
widely available nor validated. Recent efforts continue to
identify and organize karyotypic abnormalities into clinically
useful information.
The International Prognostic Scoring System (lPSS) has
been the standard prognostic system for MDS over the past
15 years. But despite an exceptional track record of clinical
value, the IPSS underweights the impact of abnormalities
associated with the poorest risk, and up to 14% of patients
will have a cytogenetic ﬁnding of undeﬁned signiﬁcance [19].
Moreover, the IPSS does not account for the differences
between isolated abnormalities and those same abnormali-
ties within a background of other ﬁndings. A recent inter-
national collaboration took up the task of reﬁning
cytogenetic risk in MDS [20]. In addition to increasing the
number of strata from 3 to 5, major departures from the IPSS
include separating the very good [-Y, del(11q)] from the good
and segregating thosewith the worst prognosis (more than 3
abnormalities) in the very poor-risk group. The new schema
provides better discrimination between risk groups but is
more unwieldy than the IPSS. Given the lack of rigorous
validation and testing in historical cohorts, molecular
markers were not included. Despite its limitations, the new
cytogentic classiﬁcation system is a considerable step
forward and has been incorporated into the highly antici-
pated revision of the IPSS (IPSS-R).
Monsosomal karyotype (MK), a subset of unfavorable-risk
ﬁndings with a particularly dismal prognosis, occurs in 10%-15% of patients with AML and is associated with a remission
rate of 18%-37% and a 4-year survival of 5%-10% [21]. Despite
occurring commonly in the presence of other adverse-risk
chromosomal abnormalities, MK portends a worse prog-
nosis compared with the adverse-risk abnormalities alone.
Furthermore, MK remains relevant in the age of molecular
markers because it typically occurs in the absence of an
establishedmolecular marker, such as FLT3-ITD orNPM1 [22].
Who Should Be Considered for Transplantation?
The decision to perform allogeneic hematopoietic cell
transplantation (HCT) for MDS and AML stands at the
intersection of constantly shifting risks. Signiﬁcant
improvement in quantifying disease risk in MDS and AML
has occurred over the past 2 decades simultaneously with
dramatic reductions in morbidity and mortality associated
with both chemotherapy and HCT. As a result, the indica-
tions for HCT versus chemotherapy continue to evolve
(Table 1). In the absence of trials with randomization
between HCT versus chemotherapy alone, we can look to
retrospective donor versus no-donor analyses to assess the
relative survival impact of allogeneic grafts. For example,
Schlenik and colleagues [23] reported that AML patients
with normal cytogenetics and FLT3-ITD mutations experi-
enced an improved relapse-free survival with HCT as
a consolidation strategy compared with chemotherapy
(Figure 2).
Evenwith the dynamic nature of HCToutcomes over time,
the general principles for identifying patients who should be
considered for HCT have not changed. Patients at high risk for
relapse after chemotherapy alone should be considered for
HCT given the ability to improve outcome in even the
highest-risk patients, such as in AML with MK [24].
Conversely, patients with the lowest-risk disease likely to be
curedwith chemotherapy alone should not be considered for
HCT. Despite the advent of novel mutations allowing for
greater precision in deﬁning disease risk, a signiﬁcant
Figure 2. Relapse-free survival in patients who achieved complete remission,
according to availability of an HLA-matched related donor. Data are shown for
patients with mutant NPM1 without FLT3-ITD (A) and for patients with other
genotypes, excluding the mutant CEBPA genotype (B). Tick marks represent
patients whose data were censored at the last time they were known to be
alive and in complete remission. (Modiﬁed with permission from Schlenk RF,
Dohner K, Krauter J, et al. Mutations and treatment outcome in cytogenetically
normal acute myeloid leukemia. N Engl J Med. 2008;366:1090-1098.)
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risk group. The evidence supporting routine recommenda-
tion of HCT in ﬁrst complete remission (CR1) remains
insufﬁcient, but is a reasonable option for many patients,
given the rates of transplant-related mortality after HCT are
falling, and will likely continue to do so. In practice, the
decision to undergo HCT in CR1 for intermediate-risk AML is
often made on a case-by-case basis. Recently, the European
LeukemiaNet developed an integrative approach that
combines both disease-related risk and the risk of trans-
plant-related mortality as predicted by composite risk scores
such as the HCT-CI [25]. It was proposed that after an indi-
vidual's risk is assessed, HCT is favored when disease-free
survival is projected to improve at least 10% with HCT over
chemotherapy alone. With continued discovery through
next-generation sequencing, the number of patients in the
heterogeneous intermediate-risk group will likely decrease
in number over time due to a better understanding of clonalevolution, identiﬁcation of new mutations, and the devel-
opment of new targeted therapeutics that modify the effect
of poor prognostic markers.
IMPACT OF MUTATIONAL ANALYSIS ON
TRANSPLANTATION OUTCOMES
The full impact of mutational analysis on transplantation
outcomes will no doubt be the subject of several articles in
the years to come. Up to now, mutational analysis has been
used primarily to identify candidates for HCT and as
a tracking tool for detecting early relapse after HCT and the
need for early posttransplantation interventions.
Investigators at the Fred Hutchinson Cancer Research
Center reported the impact of the new cytogenetic risk
classiﬁcation system and MK on outcome after HCT for MDS
or AML evolving from MDS [26]. Pre-HCT cytogenetic risk
was distinctly associated with post-HCT relapse and
mortality, and that the new classiﬁcation system discrimi-
nated more clearly among the lowest-risk and highest-risk
patients compared with the IPSS. The presence of MK was
associated with higher rates of relapse and mortality, even
after adjusting for the new classiﬁcation system, suggesting
that the system has additional prognostic power beyond
standard poor-risk or very poor-risk classes. The presence of
abnl(17p) and -5/5q- abnormalities may take this even
further, as after using a hierarchical classiﬁcation strategy,
AML patients with complex and MK have been shown to lose
their prognostic value when these marker lesions are
excluded [27]. Adverse mutations may not only confer an
inferior prognosis via increased risk of relapse alone. MDS
patients with ASXL1 mutations were demonstrated to have
inferior survival following allogeneic HCT compared to
patients without this mutation. Interestingly, the principal
cause of decreased survival appears to be a higher non-
relapse mortality [28]. With the continued discovery of novel
mutations, further data will be forthcoming regarding the
impact of HCT on survival in patients with MDS and AML,
particularly those with high-risk features.
As patients with a high risk of relapse after HCT are
identiﬁed, the all-important next step will be to introduce
strategies that modify the effect of these adverse risk factors
in an attempt to improve post-HCT outcome. Several studies
have evaluated speciﬁc targeted therapy for MDS and AML in
patients with high-risk mutational changes. Sorafenib,
a multikinase inhibitor with activity in FLT3-ITDepositive
AML, has proven beneﬁcial in pretransplantation and post-
transplantation settings in a small prospective trial [29].
However, this result is yet to be conﬁrmed by other groups.
What makes soraﬁnib particularly appealing is its possible
immunomodulatory effects in the posttransplantation
setting. In a retrospective study of 65 patients with highly
recalcitrant disease harboring FLT3-ITD mutations, sorafenib
as monotherapy was found to have an impressive response
rate, with a particularly striking result in the 29 patients who
had a previous allogeneic HCT [30]. These patients had
a lower rate of resistance to sorafenib compared with those
who had not undergone previous HCT (38% versus 47%), and
were the only patients with sustained responses. These
results suggest a possible differential effect induced by an
interaction between sorafenib and the donor cells up-
regulating the graft-versus-leukemia effect. AC220, another
FLT3 inhibitor, is currently in clinical trials for treatment of
posttransplantation relapse. As a result of next-generation
sequencing our understanding of leukemogenesis continues
to grow, and one can anticipate the emergence of new
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will prove to be useful to treat post-HCT relapse.
In addition to their use after post-HCT relapse, the use of
target agents in preventive strategies is an active area of
interest. At the Fred Hutchinson Cancer Research Center, we
are currently testing the preemptive use of AC220 after HCT
in patients with AML and MDS harboring FLT3 mutations. It
remains to be seen how the toxicity of these medications will
affect the post-transplant course and any effects they may
have on the functionality of the donor stem cells. Similarly,
protocols are currently in development for testing mid-
ostaurin, a multikinase inhibitor, in the posttransplantation
setting as prophylaxis for patients with FLT3-ITD AML and
MDS. Moreover, many additional small molecule inhibitors
are in development that are likely to be integrated into the
post-transplant setting in the near futureeeither in
a preventative strategy or as active treatment of post-trans-
plant relapse.ACKNOWLEDGMENTS
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